Cargando…

CSMD1 Mutations Are Associated with Increased Mutational Burden, Favorable Prognosis, and Anti-Tumor Immunity in Gastric Cancer

Tumor mutational burden (TMB) is considered a potential biomarker for predicting the response and effect of immune checkpoint inhibitors (ICIs). To find specific gene mutations related to TMB and the prognosis of patients, the frequently mutated genes in gastric cancer patients from TCGA and ICGC we...

Descripción completa

Detalles Bibliográficos
Autores principales:	Huang, Taobi, Liang, Yuan, Zhang, Huiyun, Chen, Xia, Wei, Hui, Sun, Weiming, Wang, Yuping
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2021
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8623648/ https://www.ncbi.nlm.nih.gov/pubmed/34828321 http://dx.doi.org/10.3390/genes12111715

Ejemplares similares

Integrated pan-cancer analysis of CSMD2 as a potential prognostic, diagnostic, and immune biomarker
por: Zhang, Huiyun, et al.
Publicado: (2022)

Prognostic Role of Tumor Mutational Burden in Cancer Patients Treated With Immune Checkpoint Inhibitors: A Systematic Review and Meta-Analysis
por: Huang, Taobi, et al.
Publicado: (2021)

Association of CSMD1 with Tumor Mutation Burden and Other Clinical Outcomes in Gastric Cancer
por: Wang, Xuning, et al.
Publicado: (2021)

CSMD3 is Associated with Tumor Mutation Burden and Immune Infiltration in Ovarian Cancer Patients
por: Lu, Nan, et al.
Publicado: (2021)

MicroRNA profiles in five pairs of early gastric cancer tissues and adjacent non-cancerous tissues
por: Liang, Yuan, et al.
Publicado: (2021)

CSMD1 Mutation Related to Immunity Can Be Used as a Marker to Evaluate the Clinical Therapeutic Effect and Prognosis of Patients with Esophageal Cancer
por: Fan, Xin, et al.
Publicado: (2021)

Rare mutations in the complement regulatory gene CSMD1 are associated with male and female infertility
por: Lee, Arthur S., et al.
Publicado: (2019)

Whole-exome sequencing associates novel CSMD1 gene mutations with familial Parkinson disease
por: Ruiz-Martínez, Javier, et al.
Publicado: (2017)

Significance of Tumor Mutation Burden Combined With Immune Infiltrates in the Progression and Prognosis of Advanced Gastric Cancer
por: Guo, Xiong, et al.
Publicado: (2021)

An updated systematic review and meta-analysis of fecal microbiota transplantation for the treatment of ulcerative colitis
por: Huang, Taobi, et al.
Publicado: (2022)

Sustained response to pembrolizumab without prior chemotherapy in high-grade serous ovarian carcinoma with CSMD3 mutation
por: Terzic, Julie, et al.
Publicado: (2020)

Comprehensive analysis of tumor mutation burden and immune microenvironment in gastric cancer
por: Yu, Jie, et al.
Publicado: (2021)

Significance of a Tumor Mutation Burden Gene Signature with Prognosis and Immune Feature of Gastric Cancer Patients
por: Xiang, Li, et al.
Publicado: (2022)

Loss of CSMD1 disrupts mammary epithelial morphogenesis
por: Kamal, M, et al.
Publicado: (2010)

The Role of Csmd1 during Mammary Gland Development
por: Burgess, Samuel J., et al.
Publicado: (2021)

Analysis of Threshold Changes of Tumor Mutation Burden of Gastric Cancer and Its Relationship with Patients' Prognosis
por: Zhang, Nan, et al.
Publicado: (2021)

ALK expression favorably impacts the prognosis of NRAS-mutated metastatic melanomas
por: Osella-Abate, Simona, et al.
Publicado: (2018)

Significance of Tumor Mutation Burden in Immune Infiltration and Prognosis in Cutaneous Melanoma
por: Kang, Kai, et al.
Publicado: (2020)

Correlation of tumor mutational burden with prognosis and immune infiltration in lung adenocarcinoma
por: Li, Lin, et al.
Publicado: (2023)

Down-Regulated CLDN10 Predicts Favorable Prognosis and Correlates With Immune Infiltration in Gastric Cancer
por: Rao, XiongHui, et al.
Publicado: (2021)

Association of RYR2 Mutation With Tumor Mutation Burden, Prognosis, and Antitumor Immunity in Patients With Esophageal Adenocarcinoma
por: Liu, Zaoqu, et al.
Publicado: (2021)

Reply to ‘Heterogeneity within AML with CEBPA mutations; only CEBPA double mutations, but not single CEBPA mutations are associated with favorable prognosis’
por: Hou, H-A, et al.
Publicado: (2009)

DNA Damage Repair Gene Mutations Are Indicative of a Favorable Prognosis in Colorectal Cancer Treated With Immune Checkpoint Inhibitors
por: Song, Yipeng, et al.
Publicado: (2021)

LRP1B mutation associates with increased tumor mutation burden and inferior prognosis in liver hepatocellular carcinoma
por: Yu, Ge, et al.
Publicado: (2022)

Favorable Immune Microenvironment in Patients with EGFR and MAPK Co-Mutations
por: Yang, Wang, et al.
Publicado: (2020)

Overexpression and mutation of ZNF384 is associated with favorable prognosis in breast cancer patients
por: Wan, Fang, et al.
Publicado: (2019)

Neuropsychological Deficits in Mice Depleted of the Schizophrenia Susceptibility Gene CSMD1
por: Steen, Vidar M., et al.
Publicado: (2013)

Assessment of Behaviors Modeling Aspects of Schizophrenia in Csmd1 Mutant Mice
por: Distler, Margaret G., et al.
Publicado: (2012)

Altered expression of the CSMD1 gene in the peripheral blood of schizophrenia patients
por: Liu, Yansong, et al.
Publicado: (2019)

Association Analyses of TP53 Mutation With Prognosis, Tumor Mutational Burden, and Immunological Features in Acute Myeloid Leukemia
por: Wen, Xiang-mei, et al.
Publicado: (2021)

Development and validation of an ECM-related prognostic signature to predict the immune landscape of human hepatocellular carcinoma
por: Wu, Guozhi, et al.
Publicado: (2022)

Persistent mutation burden drives sustained anti-tumor immune responses
por: Niknafs, Noushin, et al.
Publicado: (2023)

Role of tumor mutation burden-related signatures in the prognosis and immune microenvironment of pancreatic ductal adenocarcinoma
por: Tang, Rong, et al.
Publicado: (2021)

SYNE1 Mutation Is Associated with Increased Tumor Mutation Burden and Immune Cell Infiltration in Ovarian Cancer
por: Harbin, Laura M., et al.
Publicado: (2023)

Integration of the Tumor Mutational Burden and Tumor Heterogeneity Identify an Immunological Subtype of Melanoma With Favorable Survival
por: Gao, Yanmei, et al.
Publicado: (2020)

Significance of tumor mutation burden combined with immune infiltrates in the progression and prognosis of ovarian cancer
por: Bi, Fangfang, et al.
Publicado: (2020)

Complement inhibitor CSMD1 acts as tumor suppressor in human breast cancer
por: Escudero-Esparza, Astrid, et al.
Publicado: (2016)

Are anti-PD-1-associated immune related adverse events a harbinger of favorable clinical prognosis in patients with gastric cancer?
por: Zhang, Xiaoyun, et al.
Publicado: (2022)

LncRNA CSMD1-1 promotes the progression of Hepatocellular Carcinoma by activating MYC signaling
por: Liu, Ji, et al.
Publicado: (2020)

FAT3 Mutation Is Associated With Tumor Mutation Burden and Poor Prognosis in Esophageal Cancer
por: Guo, Zixin, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_qvjrpgsjfdli7hh926kml6t02q